Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Glaukos Corporation Common Stock (NY:GKOS)

92.99 +0.30 (+0.32%)
Official Closing Price Updated: 7:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Glaukos Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Coupa Software, Glaukos And Some Other Big Stocks Moving Higher On Wednesday
  
Via Benzinga
Glaukos Shares Pop After Positive Data From Ocular Pressure Candidate
Via Benzinga
What's Going On With Glaukos Shares?
Glaukos Corp (NYSE: GKOS) shares are trading higher by 1.87% to $49.00 Wednesday morning after the company announced topline data for both Phase 3 pivotal trials of iDose TR that successfully achieved... 
Via Benzinga
Glaukos Announces Positive Topline Outcomes for Both Phase 3 Pivotal Trials of iDose TR, Achieving Primary Efficacy Endpoints and Demonstrating Favorable Tolerability and Safety Profiles
From Glaukos Corporation
Via Business Wire
Glaukos Announces More Than 1 Million iStent® Technologies Implanted Worldwide
From Glaukos Corporation
Via Business Wire
Glaukos Inks Licensing Pact For Rare Eye Disorder Treatment
Via Benzinga
Glaukos Receives FDA 510(k) Clearance For iStent infinite
The U.S. 
Via Benzinga
Glaukos Announces Participation in the Wells Fargo Healthcare Conference
From Glaukos Corporation
Via Business Wire
Glaukos Stock Scores Rising Price Performance With Jump To 91 RS Rating
On Tuesday, Glaukos stock hit an key technical milestone, with its Relative Strength Rating climbing to 91, up from 87 the day before. 
Via Investor's Business Daily
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Glaukos: Q2 Earnings Insights
Glaukos (NYSE:GKOS) reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Glaukos missed estimated earnings by... 
Via Benzinga
Glaukos Announces FDA 510(k) Clearance of iStent infinite®
From Glaukos Corporation
Via Business Wire
Glaukos: Q4 Earnings Insights
Glaukos (NYSE:GKOS) reported its Q4 earnings results on Tuesday, February 22, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Glaukos... 
Via Benzinga
Earnings Scheduled For February 22, 2022
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is projected to report quarterly earnings at $0.13 per share on revenue of $439.63 million. • Sohu... 
Via Benzinga
Glaukos Corporation Announces Second Quarter 2022 Financial Results
From Glaukos Corporation
Via Business Wire
Glaukos to Release Second Quarter 2022 Financial Results after Market Close on August 3
From Glaukos Corporation
Via Business Wire
The 6 Most Aggressive Growth Stocks to Buy in July
These are the 6 most aggressive growth stocks to buy in July. They reflect huge potential growth in their sales and/or their earnings. 
Via InvestorPlace
Glaukos Announces Participation in the William Blair Growth Stock Conference
From Glaukos Corporation
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For July 12, 2022
Upgrades 
Via Benzinga
Glaukos Announces Participation in the Piper Sandler Virtual Ophthalmology Symposium
From Glaukos Corporation
Via Business Wire
Glaukos Corporation Announces First Quarter 2022 Financial Results
From Glaukos Corporation
Via Business Wire
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting
From Glaukos Corporation
Via Business Wire
Glaukos Announces the Release of its 2021 Sustainability Report
From Glaukos Corporation
Via Business Wire
Glaukos to Release First Quarter 2022 Financial Results after Market Close on May 4
From Glaukos Corporation
Via Business Wire
Sight Sciences' Q4 Earnings, FY22 Guidance Beat Street View
Sight Sciences Inc (NASDAQ: SGHT) has treated the first patient in the TRIDENT trial evaluating OMNI Surgical System compared to Glaukos Corp's (NYSE... 
Via Benzinga
Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink™ Therapy
From Glaukos Corporation
Via Business Wire
Glaukos Corporation Announces Fourth Quarter and Full Year 2021 Financial Results
From Glaukos Corporation
Via Business Wire
Glaukos Announces Executive Leadership Changes
From Glaukos Corporation
Via Business Wire
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2022
Upgrades BTIG upgraded the previous rating for Insulet Corp (NASDAQ:PODD) from Neutral to Buy. For the third quarter, Insulet had an EPS of $0.18, compared to year-ago... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.